πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 120 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11173165

Optimizing mifepristone levels for Cushing's patients

Corcept Therapeutics Incorporated Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11103514

Treatment of muscular dystrophy

Corcept Therapeutics Incorporated Β· Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11073523

Method for differentially diagnosing ACTH-dependent Cushing's syndrome

Corcept Therapeutics Incorporated Β· Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11058670

Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid rece

Corcept Therapeutics Incorporated Β· Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11045482

Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumo

Corcept Therapeutics Incorporated Β· Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10980797

Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10973813

Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10946005

Methods for shrinking pituitary tumors

Corcept Therapeutics Incorporated Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10898478

Glucocorticoid receptor modulators to treat cervical cancer

Corcept Therapeutics Incorporated Β· Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10881660

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagoni

Corcept Therapeutics Incorporated Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10842800

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10842801

Optimizing mifepristone absorption

Corcept Therapeutics Incorporated Β· Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10828280

Glucocorticoid receptor modulators to treat pancreatic cancer

Corcept Therapeutics Incorporated Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10787449

Octahydro fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10780097

Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with gl

Corcept Therapeutics Incorporated Β· Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10660904

Optimizing mifepristone levels for cushing's patients

Corcept Therapeutics Incorporated Β· Granted Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10646474

Glucocorticoid receptor modulators to treat pancreatic cancer

Corcept Therapeutics Incorporated Β· Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10610534

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated Β· Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10604807

Methods for diagnosing and assessing treatment for Cushing's syndrome

Corcept Therapeutics Incorporated Β· Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10568880

Glucocorticoid receptor modulators to treat cervical cancer

Corcept Therapeutics Incorporated Β· Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10500216

Optimizing mifepristone absorption

Corcept Therapeutics Incorporated Β· Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10495650

Method for differentially diagnosing ACTH-dependent Cushing's syndrome

Corcept Therapeutics Incorporated Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10456392

Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10449178

Glucocorticoid receptor modulators to treat pancreatic cancer

Corcept Therapeutics Incorporated Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted